Rising Biosciences (Rising Biosciences) Change In Receivables : $0.00 Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Change In Receivables?

Rising Biosciences's change in receivables for the quarter that ended in . 20 was $0.00 Mil. It means Rising Biosciences's Accounts Receivable stayed the same from . 20 to . 20 .

Rising Biosciences's change in receivables for the fiscal year that ended in . 20 was $0.00 Mil. It means Rising Biosciences's Accounts Receivable stayed the same from . 20 to . 20 .

Rising Biosciences's Accounts Receivable for the quarter that ended in . 20 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Rising Biosciences's liquidation value for the three months ended in . 20 was $0.00 Mil.

Rising Biosciences Change In Receivables Historical Data

The historical data trend for Rising Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Change In Receivables Chart

Rising Biosciences Annual Data

Trend

Change In Receivables

Rising Biosciences Quarterly Data

Change In Receivables

Rising Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rising Biosciences (GREY:RBII) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Rising Biosciences's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Rising Biosciences's accounts receivable are only considered to be worth 75% of book value:

Rising Biosciences's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Rising Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.